Hans Lee on increasing US representation in global clinical trials
Dr. Hans Lee leads a discussion at 12:30 pm CST on September 2, 2026, on increasing US representation in global clinical trials.
Dr. Hans Lee leads a discussion at 12:30 pm CST on September 2, 2026, on increasing US representation in global clinical trials.
Dr. Marin Xavier leads a discussion at 3:00 pm CST on August 11, 2026, on integrating new evidence into everyday practice.
Dr. Gwen Nichols leads a discussion at 12:15 pm CST on July 13, 2026, on addressing funding gaps in blood cancer research.
SOHO Asia 2026 will focus on the latest advances in leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms (MPNs), featuring leading experts from across
The US Food and Drug Administration accepted and granted priority review to a new drug application for sonrotoclax, a next-generation BCL2 inhibitor, for
Dr. Jeff Sharman leads a discussion at 11:30 am CST on May 15, 2026, on exploration of barriers and solutions for activating and
The US Food and Drug Administration has approved lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or
Krish Patel presents at 1:15 pm CST on April 15, 2026, on building partnerships between community and academic centers.
The United States Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with
Held on March 18, 2026, from 12:30–1:00 PM CST with Jeffrey Matous presenting "Managing Access to Novel Agents in the Community Setting."